Effect of Flozin (dapagliflozin) Administration on Myocardial and Peripheral Vascular Remodeling

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Total Enrollment

50 participants

Study Classification

OBSERVATIONAL

Study Start Date

2023-03-10

Study Completion Date

2026-02-28

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The aim of this study is to assess the effect of treatment with flozin (dapagliflozin 10mg once a day) on haemodynamic parameters and myocardial and peripheral vascular remodeling in patients with NYHA class II-III heart failure.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Short-term Effects of Dapagliflozin on Peak VO2 in HFrEF

NCT04197635

Heart Failure With Reduced Ejection Fraction

COMPLETED PHASE4

Effects of Dapagliflozin on Cardiorespiratory Parameters in Heart Failure

NCT05770167

Heart Failure Heart Failure With Reduced Ejection Fraction Left Ventricle Remodeling +2 more

UNKNOWN

DETERMINE-reduced - Dapagliflozin Effect on Exercise Capacity Using a 6-minute Walk Test in Patients With Heart Failure With Reduced Ejection Fraction

NCT03877237

Heart Failure With Reduced Ejection Fraction (HFrEF)

COMPLETED PHASE3

CAMEO-FONTAN -Dapagliflozin in the Failing Fontan Circulation

NCT06762964

Fontan Circulation Single Ventricle Heart Disease HFpEF - Heart Failure With Preserved Ejection Fraction

RECRUITING PHASE2

Empagliflozin and Dapagliflozin in Patients Hospitalized for Acute Decompensated Heart Failure

NCT05776043

Acute Decompensated Heart Failure

RECRUITING PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

In the available literature, there are reports of beneficial effects of flozins on improving myocardial systolic and diastolic function and isolated reports of effects on regression of organ damage (heart, vessels). These drugs significantly improve the prognosis of patients with heart failure, reduce total and cardiovascular mortality, reduce the number of exacerbations and the need for hospitalization, and have a beneficial effect on improving quality of life regardless of coexisting diabetes. New properties demonstrating the pleiotropic effect of the flozins are constantly being discovered. Drugs in this group are highly potent, selective and reversible inhibitors of the sodium ion-dependent glucose cotransporter 2 (SGLT2). The flozins have a low risk of side effects.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Heart Failure

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

OTHER

Study Time Perspective

PROSPECTIVE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* diagnosed heart failure NYHA class II and III
* consent to participate in the study
* patients should already be receiving treatment with an ACE inhibitor or sacubitril/valsartan or sartans, a beta-blocker, and an MRA, and should start on SGLT2i as part of therapy enhancement